Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies
Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.
EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management
EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients
EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment
EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy
EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
EP: 6.Evaluating Safety of Novel LDL Management Mechanism
EP: 7.Examining Results from VICTORION-INITIATE Trial
EP: 8.Other Notable Emerging Lipid-Lowering Treatments
EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents
EP: 10.Diabetes, GLP-1, and Lipid Reduction
EP: 11.Medication Adherence in Patients with High LDL Cholesterol
Now Viewing
EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies
EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole
Video content above is prompted by the following questions:
- How does your office handle payer approval/prior authorization for lipid lower medication? Are there any tips to help with getting approval?
- How is help with co pay assistance programs coordinated in your practice to help increase accessibility and affordability?
Recent Videos
Related Content
